AUTO3 CAR T-Cell Product Plus Pembrolizumab Shows Clinical Activity, Tolerability in Relapsed/Refractory DLBCL


The investigational CAR T-cell product AUTO3 in combination with pembrolizumab was found to have a tolerable safety profile and elicit durable complete responses in patients with relapsed/refractory diffuse large B-cell lymphoma.

The investigational CAR T-cell product AUTO3 in combination with pembrolizumab (Keytruda) was found to have a tolerable safety profile and elicit durable complete responses (CRs) in patients with relapsed/refractory diffuse large B-cell lymphoma (DLBCL), according to results of the single-arm, phase 1/2 ALEXANDER study that were presented during the virtual 2020 ESMO Congress.1

Findings showed that across 4 cohorts with varying doses of AUTO3 alone or in combination with pembrolizumab, the objective response rate (ORR) was 68% (n = 19/28) and the CR rate was 54%. Four patients had a partial response (PR), and 9 patients had progressive disease (PD).

When stratified by a cohort that comprised the recommended phase 2 dose, which was 150-450 x 106 AUTO3 plus pembrolizumab on day minus 1 (n = 20), the ORR was 71%, including a 64% CR rate. Here, 1 patient achieved a PR and 4 patients had PD.

“AUTO3 is safe and well tolerated, with its best-in-class safety profile. The complete remission rates of the recommended phase 2 cohort appear promising, with overall durable remissions noted for the product,” lead study author Eleni Tholouli, MD, consultant hematologist at NHS Foundation Trust, said in a virtual presentation during the meeting.

AUTO3 is a first-in-human bicistronic CD19- and CD22-directed CAR T-cell therapy. The agent was designed in an effort to reduce the risk of relapse that is due to single antigen loss in patients with B-cell malignancies.2

The single-arm open-label, multicenter, phase 1/2 study comprised a dose-escalation cohort and an efficacy cohort. In the phase I dose-escalation cohort (n = 30), preconditioning fludarabine and cyclophosphamide were given, and patients were treated with AUTO3 at varying doses, along with pembrolizumab on either day 14 for 3 doses, or on day minus 1 for 1 dose. AUTO3 was infused at a starting dose of 50 x 106 CD19/CD22 CAR T cells.

In the phase 2 efficacy stage, there were 2 cohorts. Cohort 1 was comprised of patients with DLBCL not otherwise specified (NOS), high-grade B-cell lymphoma, and transformed DLBCL (tDLBCL) from follicular lymphoma; all received more than 2 prior lines of therapy. Cohort 2 included patients with primary mediastinal large B-cell lymphoma and tDLBCL from other indolent non-Hodgkin lymphoma; these patients also received over 2 lines of previous treatment.

All except the first 3 patients in cohort 1 received consolidation preconditioning therapy with pembrolizumab, Tholouli added.

In total, investigators enrolled 35 patients with DLBCL (n = 25), comprising both germinal center B-cell ([GCB], n = 17) and non-GCB (n = 8); tDLBCL from follicular lymphoma (n = 7) and from marginal zone lymphoma (n = 1); and high-grade B-cell lymphoma (n = 2). Most patients had stage IV disease (n = 22), followed by stage III (n = 9), stage II (n = 3), and unknown (n = 1).

The median age was 59 years (range, 28-83), and 23 patients were male. Nineteen patients had both relapsed and refractory disease, 7 patients had refractory, and 9 patients had relapsed disease. Additionally, patients had low-risk disease as assessed by International Prognostic Index (n = 4), low-intermediate risk (n = 6), high-intermediate risk (n = 10), high-risk (n = 4), and unknown (n = 11). The median number of prior therapies was 3 (range, 1-10), and 8 patients underwent prior autologous stem cell transplant. The median sum of the product of diameters (SPD) was 19.31 cm (2.1-260.84).

“The median SPD shows that the tumor burden is, in this trial, similar to that of other CD19[-directed] CAR T trials,” said Tholouli.

The varying dose levels were as follows: 50 x 106 AUTO3 with no pembrolizumab (n = 4), 50 x 106 AUTO3 with pembrolizumab on day 14 (n = 3), 150-450 x 106 AUTO3 on day 14 with pembrolizumab (n = 8), and 150-450 x 106 AUTO3 with pembrolizumab on day minus 1 (n = 20).

No severe cytokine release syndrome (CRS) was reported in any patients on study. Grade 1 CRS was reported in 8 patients (22.9%) and occurred in 3 of the 4 dose levels: 50 x 106 AUTO3 (n = 1), 150-450 x 106 AUTO3 with pembrolizumab on day 14 (n = 2), and 150-450 x 106 AUTO3 with pembrolizumab on day minus 1 (n = 5). Grade 2 CRS occurred in 4 patients (11.4%) and was reported in 2 patients each of both 150 to 450 x 106 AUTO3 cohorts.

Tholouli noted that 1 patient who had no CRS with primary infusion later developed grade 3 CRS with severe hypoxia with re-treatment 1 year later, which occurred in a setting of no CAR T-cell expansion and significant disease burden in the lung, which had been treated with radiation.

No prophylactic measures were given, but 5 patients (14%) required tocilizumab (Actemra) for CRS. The median time to CRS was 6 days (range, 1-36), and the median duration of CRS was 3 days (range, 1-19).

“Based on our experience, this profile appears clearly superior to that of currently approved CD19-directed CAR T-cell products,” Tholouli said.

Three cases (n = 8.6%) of neurotoxicity were reported across the population, 2 were grade 3 or higher and occurred at the 50 x 106 AUTO3 level (n = 1) and the 150 to 450 x 106 AUTO3 with pembrolizumab on day minus 1 dose (n = 1). Similar to the CRS data, no prophylactic measures were needed.

Tholouli added that no any-grade neurotoxicity occurred in patients who achieved a CR, which were also patients who had robust expansion. All cases of neurotoxicity were atypical in context of tumor progression, with no to minimal CAR-T expansion in the peripheral blood.

In the patient with grade 2 neurotoxicity, their mental status was altered and associated with sepsis and narcotics and resolved. In the patients with grade 3 neurotoxicity, Tholouli said that they experienced facial and muscle weakness that was onset on day 53 but resolved. Finally, in the patient with grade 4 neurotoxicity, encephalopathy was experienced and was associated with sepsis, hyponatremia overcorrection to hypernatremia, metabolic acidosis, and multiorgan failure. The patient died from disease progression and multiorgan failure.

Twenty-eight of the 35 patients were evaluable for response, and responses were reported at all dose levels. In the 50 x 106 AUTO3 cohort with no pembrolizumab (n = 4), 2 patients achieved a response, with 1 CR and 1 PR; 2 patients experienced PD. In the cohort of those who received 50 x 106 AUTO3 with pembrolizumab on day 14 (n = 3), 2 responses were observed—1 CR and 1 PR, but no patients experienced PD. In patients who were treated with 150 to 450 x 106 AUTO3 with pembrolizumab on day 14 (n = 8), 5 patients had a response, which comprised of 4 CRs and 1 PR; 3 patients experienced PD.

At a median follow-up of 6 months (range, 1-24), 93% of patients who achieved CRs did not develop PD.

“Most interestingly, CRs appear to be durable,” Tholouli said. “Only 1 patient developed PD after achieving a CR, and this was patient treated at the lowest dose of [50 x 106 AUTO3] and without pembrolizumab.”

Based on these findings, Tholouli concluded that an ongoing expansion cohort with the recommended phase 2 dosing in the outpatient setting is currently enrolling in the United States and the United Kingdom.


  1. Tholouli E, Ardeshna K, Ramakrishnan A, et al. Phase I Alexander study of AUTO3, the first CD19/22 dual targeting CAR T cell therapy, with pembrolizumab in patients with r/r DLBCL. Presented at: 2020 ESMO Congress; September 19-21, 2020; virtual. Abstract 890M0.
  2. Autolus Therapeutics presents additional data on AUTO3 in DLBCL during the ASCO20 Virtual Scientific Program. News release. Autolus Therapeutics. May 29, 2020. Accessed September 23, 2020.
Related Videos
Saurabh Dahiya, MD, FACP, associate professor, medicine (blood and marrow transplantation and cellular therapy), Stanford University School of Medicine, clinical director, Cancer Cell Therapy, Stanford BMT and Cell Therapy Division
Lori A. Leslie, MD
James Ignatz-Hoover, MD, PhD
Changchun Deng, MD, PhD
Sundar Jagannath, MBBS
Guenther Koehne, MD, PhD
Krina K. Patel, MD, MSc
Ibrahim Aldoss, MD
Olalekan O. Oluwole, MBBS, MD, associate professor, medicine, hematology/oncology, Vanderbilt Institute for Infection, Immunology and Inflammation, Vanderbilt University Medical Center
Andrew P. Jallouk, BS, MD, PhD, assistant professor, Vanderbilt University